Pallas Capital Advisors LLC Has $992,000 Stake in IQVIA Holdings Inc. (NYSE:IQV)

Pallas Capital Advisors LLC increased its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 270.6% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 5,629 shares of the medical research company’s stock after acquiring an additional 4,110 shares during the period. Pallas Capital Advisors LLC’s holdings in IQVIA were worth $992,000 as of its most recent filing with the SEC.

A number of other hedge funds have also made changes to their positions in the stock. Howard Capital Management Inc. increased its holdings in shares of IQVIA by 4.9% during the 4th quarter. Howard Capital Management Inc. now owns 1,147 shares of the medical research company’s stock valued at $225,000 after acquiring an additional 54 shares during the last quarter. Continuum Advisory LLC grew its holdings in IQVIA by 3.7% in the 4th quarter. Continuum Advisory LLC now owns 1,803 shares of the medical research company’s stock valued at $354,000 after buying an additional 64 shares during the last quarter. ST Germain D J Co. Inc. grew its holdings in IQVIA by 66.1% in the 1st quarter. ST Germain D J Co. Inc. now owns 191 shares of the medical research company’s stock valued at $34,000 after buying an additional 76 shares during the last quarter. New York Life Investment Management LLC raised its stake in shares of IQVIA by 0.4% in the fourth quarter. New York Life Investment Management LLC now owns 23,086 shares of the medical research company’s stock valued at $4,537,000 after purchasing an additional 81 shares in the last quarter. Finally, Zions Bancorporation N.A. lifted its position in IQVIA by 55.2% in the fourth quarter. Zions Bancorporation N.A. now owns 239 shares of the medical research company’s stock worth $47,000 after purchasing an additional 85 shares during the period. Institutional investors and hedge funds own 89.62% of the company’s stock.

IQVIA Stock Performance

Shares of NYSE:IQV opened at $159.70 on Wednesday. The stock has a market capitalization of $27.63 billion, a P/E ratio of 21.29, a P/E/G ratio of 1.99 and a beta of 1.28. IQVIA Holdings Inc. has a 1-year low of $134.65 and a 1-year high of $252.88. The business has a 50-day moving average price of $147.13 and a two-hundred day moving average price of $178.43. The company has a current ratio of 0.84, a quick ratio of 0.84 and a debt-to-equity ratio of 2.12.

IQVIA (NYSE:IQV) last posted its earnings results on Tuesday, May 6th. The medical research company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.63 by $0.07. The company had revenue of $3.83 billion during the quarter, compared to analyst estimates of $3.77 billion. IQVIA had a return on equity of 28.81% and a net margin of 8.91%. The company’s revenue for the quarter was up 2.5% compared to the same quarter last year. During the same period in the previous year, the company earned $2.54 EPS. Equities analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.

Analysts Set New Price Targets

Several research analysts recently commented on IQV shares. Citigroup reaffirmed a “neutral” rating on shares of IQVIA in a research report on Thursday, May 22nd. Morgan Stanley lifted their price objective on IQVIA from $245.00 to $250.00 and gave the company an “overweight” rating in a report on Tuesday, February 11th. Mizuho cut their price objective on IQVIA from $210.00 to $190.00 and set an “outperform” rating for the company in a report on Thursday, May 15th. Redburn Partners set a $188.00 price objective on IQVIA in a report on Friday, May 23rd. Finally, Robert W. Baird cut their price objective on IQVIA from $195.00 to $161.00 and set a “neutral” rating for the company in a report on Wednesday, May 7th. Eight investment analysts have rated the stock with a hold rating, sixteen have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, IQVIA currently has a consensus rating of “Moderate Buy” and a consensus target price of $226.32.

IQVIA Profile

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.